Capstone Therapeutics Corp Stock Other OTC
Equities
US14068E1091
Biotechnology & Medical Research
Financials (USD)
Sales 2022 | 61.56M | Sales 2023 | 48.35M | Capitalization | 820K |
---|---|---|---|---|---|
Net income 2022 | 2M | Net income 2023 | -3M | EV / Sales 2022 | 0.56 x |
Net Debt 2022 | 28.78M | Net Debt 2023 | 20.28M | EV / Sales 2023 | 0.44 x |
P/E ratio 2022 |
-583
x | P/E ratio 2023 |
-0.14
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 100% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Toporek
CEO | Chief Executive Officer | 59 | 17-07-13 |
Edward Schultz
DFI | Director of Finance/CFO | - | - |
Matthew Lipman
BRD | Director/Board Member | 45 | 17-07-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jock Holliman
BRD | Director/Board Member | 70 | 87-08-31 |
Michael Toporek
CEO | Chief Executive Officer | 59 | 17-07-13 |
Matthew Lipman
BRD | Director/Board Member | 45 | 17-07-13 |
1st Jan change | Capi. | |
---|---|---|
+3.13% | 43.43B | |
+48.60% | 41.69B | |
+8.49% | 41.31B | |
-10.82% | 27.14B | |
+8.26% | 25.28B | |
-23.69% | 18.47B | |
+1.58% | 12.33B | |
+32.83% | 12.59B | |
+6.63% | 11.03B |